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Summary
Corticosteroids (CSs) are still the mainstay of induction, rescue, and maintenance
in heart transplantation (HTx). However, their use is associated with significant
and well-documented side effects usually related to the dose administered and the
duration of therapy. Moreover, CSs interfere with the recipient’s quality of life
and with the active process of graft tolerance. Physicians have been exploring ways
to avoid or reduce CSs in association with other immunosuppressive drugs, mini-
mizing side effects and costs. The regimens are classified as steroid-free or steroid
withdrawal protocols. The studies analyzed in this review come to similar conclu-
sions as benefits and adverse consequences: steroid-free protocols should be advis-
able and mandatory in pediatric patients, insulin-dependent diabetes mellitus
(IDDM), presence of infection, familial metabolic disorders/obesity, severe osteo-
porosis, and in the elderly. On the other hand, steroid withdrawal can be success-
fully achieved in 50–80%, with late better than early withdrawal, no increase in
rejection-related mortality, no adverse impact on survival, and probably a better
quality of live. Safety and efficacy can certainly be improved by an individualized
approach to the transplant recipient.
Introduction
Every year, about 4000 heart transplantations (HTx) are
performed worldwide according to the ISHLT registry.
Median survival is steadily improved from 8.5 years (1982–
1992) to 10.9 years (1993–2002), and it is further improved
since 2003 [1]. Acute rejection is now a fairly uncommon
cause of death, being responsible for no more than 11% of
deaths, whereas graft failure of different origin is the leading
cause of death in the first 30 days after transplant and later.
Even if the exact etiology of late graft failure is unknown,
deaths are mainly due to cardiac allograft vasculopathy
(CAV), an immunomediated process possibly worsened by
other comorbidities as hypertension, diabetes mellitus, and
hyperlipidemia. These deaths can at least in part be attrib-
uted to the effects of immunosuppressive therapies [1].
Calcineurin inhibitors (CNIs), mycophenolic acid (MPA),
mammalian target of rapamycin inhibitors (mTOR), and
corticosteroids therapy continue to be the dominant
immunosuppressive choice after HTx [1]. CSs are a
standard part of every phase of immunosuppression
(induction, maintenance, rejection treatment). Their use is
associated with significant and well-documented side
effects usually related to the dose administered and the
treatment duration [2,3]. The most frequent and distress-
ing side effects of steroid association in transplant recipi-
ents are metabolic [4–8], skeletal [9–12], and vascular
disorders [13], often combined with a higher susceptibility
to infections [14].
The optimal immunosuppressive therapy is the
combination of different drugs to enhance their immuno-
suppressive potential and decrease their toxic effects by
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lowering the single dosage of each, also allowing the reduc-
tion or suppression of steroids. Thus, physicians have been
exploring ways to avoid or eliminate the need for long-term
steroid treatment, thereby minimizing side effects and
costs. These regimens classified as steroid-free or steroid
withdrawal protocols (early within the first 3–6 months
after HTx or late between 6–12 months and beyond post-
transplant) have been applied in several solid organ trans-
plantations.
In the early 1980s, the European transplant community
tried to withdraw from standard immunosuppression or
avoid completely the use of CSs in organ transplantation,
but the results were varied and might be not applicable to
the actual therapies [15,16]. Instead, in a more recent
analysis, Lerut [17] evaluated studies using more innovative
drugs and concluded that results were satisfying in almost
all types of solid organ transplants if steroid avoidance had
been accomplished. Moreover, the same author reported
that in clinical practice of liver transplantation, there was a
tendency toward steroids minimization with their avoid-
ance more favorable than their withdrawal [18]. CS mini-
mization protocols and sparing have been applied even in
kidney transplantation [19,20], and a meta-analysis of
Knight SR et al. [21] revealed an increase in the risk of
acute rejection (AR) with steroid avoidance or withdrawal
protocol (RR 1.56, CI 1.31–1.87, P < 0.0001), but with no
measurable effect on graft or patient survival, reporting at
the same time significant benefits in cardiovascular risk
profile. Steroid withdrawal in pancreas and islet transplan-
tation, even if the success has been validated by several
transplant centers, cannot currently be recommended
because lacking in prospective randomized studies to verify
the risk/benefit ratio [22,23].
The first to describe results with steroid-free immunosup-
pression in HTx was Yacoub et al. [24] in 1985, whereas
the first experience with steroid withdrawal was reported
by Pritzker et al. [25]. Moreover, this therapeutic approach
was proven to be feasible also in pediatric HTx [26,27].
Experience with the minimization of CSs in heart trans-
plantation is relatively poor and more heterogeneous when
compared with other solid organs, and results are difficult
to interpret. In fact, the clinical use of different CSs minimi-
zation protocols and different co-treatments in various
clinical settings might make clinical outcomes difficult to
compare. Thus, the purpose of this paper was to focus only
on CSs-free and CSs-withdrawal protocols in HTx patients
to evaluate the results achieved on survival, rejection and
infection rate, or other drug side effects.
The role of steroids in heart transplantation
CSs immunosuppressive action is multifactorial depending
on the target cell type considered and their activation state:
(i) synthesis of lipocortins which prevent arachidonic acid
release from membrane-bound stores; (ii) blockade of
selected elements of the signal transduction pathways that
operate as a consequence of T-cell activation; (iii) inhibi-
tion of leukocyte adhesion molecule expression; and (iv)
suppression of cytokine production and action [28]. To
influence cellular function, CSs must enter the cell and bind
to and activate intracellular receptors, named glucocorticoid
receptors (GRs), type-I and type-II [29]. Type-II GRs,
widely distributed in the immune system, affect all immune
cells at an intermediate level in mature T and B cells and at
very low level in neutrophils [30]. GRs density in peripheral
T cells is a critical determinant of sensitivity, and despite
the presence of functional GRs, clinical CSs resistance can
arise [31]. It has been demonstrated that chronically CSs
drug therapy may alter immune cell differentiation which
may be of relevance in the induction of peripheral tolerance
to allergenic stimuli [32–35].
The main CSs used to prevent and treat allograft rejec-
tion are prednisolone and prednisone. From a pharmacoki-
netic point of view, synthetic CSs present increased
bioavailability, poor linkage to CS-binding globulin
(CBG) and have much longer half-life than endogenous
CSs (cortisol, corticosterone) [36,37]. CSs administration
to humans results in rapid but transient lymphopenia
(especially T cells) [38] and in a significant reduction in
eosinophil and basophil numbers, whereas vice versa neu-
trophil exhibits a marked increase [39]. In clinical setting,
beside the well-known effect on acute rejection, CSs
could impact also on coronary allograft vasculopathy
(CAV), present in 90% of patients within 10 years and
considered one of the major cause of late death following
HTx [40–43]. Etiology of CAV is mostly immunologic,
but nonimmune pathways contribute to its development.
Inflammatory cells and humoral injuries are present in
evolving lesions [44]; cytokines and chemokines are
known to mediate local and systemic immune responses
and to recruit and activate inflammatory cells. Thus, CS
minimization might accelerate the course of CAV being
the disease for great part immunomediated. However,
Ratkovec et al. [45] demonstrated that CSs minimization
does not adversely affect the prevalence or progression of
CAV during the first 2 years after HTx. Moreover, while
cyclosporine and tacrolimus are not effective in prevent-
ing CAV [46], mychophenolate mofetil, sirolimus, and
everolimus seem to impact on the appearance and pro-
gression of CAV, allowing a consistent reduction in CSs
[47–49].
As it has been demonstrated that cumulative CSs dose in
HTx recipients has been associated with hyperlipidemia
and possibly with more diabetes and hypertension, CSs
withdrawal or avoidance would decrease the incidence and
progression of CAV [50].
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Methods
This review is focusing on strategies to avoid CSs after HTx
as a means to improve short- and long-term outcome. To
analyze the impact of different CSs protocols, we searched
the PubMed database up to June 2013 using the following
keywords: heart transplantation, corticosteroids, steroid-free,
complete steroid avoidance, steroid withdrawal, steroid mini-
mization, and steroid side effects. Inclusion criteria specified
any prospective or retrospective trial or observational study
in adult and pediatric HTx recipients. This research was
considering only studies that compared steroid groups
(SG) versus steroid-free groups (SFG). Studies with steroid
avoidance [steroid free = SF], with early steroid withdrawal
(within the first 6 months) [early withdrawal in steroid,
free maintenance immunosuppression = ew-SFM], and
late steroid withdrawal (between 6 and 12 months and
beyond post-HTx) [late withdrawal in steroid-free mainte-
nance immunosuppression = lw-SFM] regimens, including
pediatric experiences, were then analyzed separately.
Quality assessment was performed according to the
Cochrane Collaboration Criteria for the evaluation of RCTs
[51] and according to the GRACE principles for the evalua-
tion of observational studies [52]. For the evaluation of
RCTs, only internal validity criteria were computed for the
final 10-points score (for each item, a yes/no/unclear evalu-
ation was made; then, 1 point was assigned for each posi-
tive mark). For the evaluation of observational studies, an
overall assessment was performed in accordance with
GRACE principles, ranking studies as low, medium, or high
quality. Considering the different quality levels, the variety
in patients’ characteristics, the fact that most studies had
only one arm and that evaluation of the outcomes was dif-
ferent among studies, a meta-analysis was not attempted.
Patients were divided in steroid group (SG) and steroid-free
(maintenance) group (SFG). To compare the results of the
studies, the following parameters were selected: graft and
patient survival, rejection and infection rate, or other compli-
cations. Results of comparison among different drug ther-
apy approaches and relative quality assessment results are
reported in Tables 1–4. Finally, authors’ conclusions were
compared.
Results
Twenty-one studies were finally included in the review.
Beyond what is shown in the tables, other findings will be
highlighted in bold. Most studies were actually well con-
ducted, but analyses were sometimes not appropriate for
the outcome or conducted “as treated”, so providing the
reader with only the ideal efficacy of the treatment. More-
over, in only very few studies, a multivariable modeling was
applied.
Steroid-free immunosuppression
There are few data on CSs avoidance in adult HTx, three
prospective [53,54,56] and one retrospective [55] com-
pared HTx results in SG versus SFG (Table 1). Only one
paper was of high quality [55], and three were of low qual-
ity [53,54,56]. The reported 2-year survival was excellent
either in SG and SFG without any significant differences
(92% and 93% in the first study, 86% and 85% in the sec-
ond, respectively) [53,54]. When evaluating prospective
studies only, the incidence of acute rejection was found to
be significantly higher in SFG versus SG in two studies
[53,54] and lower in one [56]. On the contrary, the overall
incidence of infections was significantly higher [53] or sim-
ilar [54,56] in SG than SFG. The use of steroids was joined
with increased antihypertensive drug use [54], vice versa
reduction in bone loss and better cardiac function were
recorded in the SFG [56]. Overall, it can be concluded that
steroids-free therapies appear to be safe because of the good
survival even in the presence of a higher rejection rate, with
the incidence of infections being similar.
In the only retrospective study, rated as “high quality”,
dealing with 112 consecutive HTx patients initially immu-
nosuppressed with CsA+AZA without CSs, Livi et al. [55]
recorded good survival of discharged patients at 1 year and
2 years (95% and 94%, respectively), high incidence of
acute rejection, and lower trend in hypertension incidence.
The authors concluded that despite the more frequent
occurrence of acute rejection, the excellent mid-term sur-
vival and the initial low incidence of both infection and
chronic rejection justified a wider use of such treatment.
Beyond our primary end points, there are other aspects
worthy to be considered. In a randomized prospective trial,
Jones et al. compared the quality of life after HTx in
patients treated with CsA+AZA (double therapy) versus
CsA+AZA+CSs (triple therapy). Patients who received dou-
ble therapy showed advantages in 10 of 11 measures of life
quality with significant differences in score of anxiety, sex-
ual activity, and physical well-being. Furthermore, patients
who received double therapy reported a lower frequency of
and less distress from the immunosuppression side effects
with return to full-time employment and better weight
control [57].
Steroid withdrawal immunosuppression
Experience with SFM protocol is large and highly variable
depending on the dose, on the duration of CSs therapy,
and on the other immunosuppressive drugs used. Based on
this, it is not easy to compare different studies and clinical
outcomes. In different publications, we found several pro-
tocols which can be simplified in early withdrawal (ew) and
late withdrawal (lw) CSs protocols.
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The ew-CSs protocol was reported in one prospective
[25] and two retrospective trials [58,59] (Table 2). All these
studies were classified as high quality. The long-term sur-
vival in SFM group was significantly higher than SG in all
the studies analyzed [25,58,59].
Comparing the groups about rejection episodes, results
appear even more controversial. In fact, while some authors
agreed that SG experienced better freedom from rejection
(P < 0.01) [59], others showed that the ew-CSs protocols
were associated with a lower incidence of rejection
(P = 0.0002) in one study [58] or with similar results
(P = 0.910) in the other [25].
Considering the incidence of infections, Pritzker et al.
[25] reported similar infective complication rates in both
the groups (P = 0.091), whereas Taylor et al. revealed that
treated infections were more common in patients in whom
early CS weaning failed [58]. Similarly, Rosenbaum et al.
[59] observed that freedom from infections did not differ
between the two groups considered (P = 0.10). Moreover,
the same authors observed better overall freedom from
malignancy in SFM group (skin cancer, P < 0.01), while
post-transplant morbidities (renal dysfunction, obesity,
diabetes, CAV) were similar in both the groups. Also, Tay-
lor observed that CAV was apparently lower in the SFM
group, albeit not significant, (P = 0.10), and in other stud-
ies, SFM protocol seemed to be associated with lower lipid
values, less hypertension, and better or similar weight con-
trol [25,59].
The lw-CSs protocol was reported in 10 papers, four pro-
spective trials [61,64,65,69], and six retrospective
[60,62,63,66–68] (Table 3). Five studies were of high qual-
ity and five of medium quality. Of the four prospective
studies, only one was rated as “high quality” [64]; Opelz
et al. [65] focused on mortality reporting 7-year survival
rate significantly higher in SFM group (P = 0.0008). Rejec-
tion rate was similar in both the groups according to Del-
gado (P = 0.825) [61] and Opelz (P = 0.148) [65], whereas
Mehra reported lower rate in SFM compared with SG
(P = 0.04) [64]. The incidence of severe infections was sim-
ilar in both the groups [61] or significantly more frequent
in SG compared with SFM (P < 0.001) [64]. SFM groups
experienced lower level of total cholesterol (P = 0.008) and
a trend toward lower rate of hypertension [65].
In retrospective studies, the reported survival rates were
higher according to Felkel (5 years: 93% in SFM group ver-
sus 77% in SG (P < 0.0001) [63], whereas it was similar
between the two groups as reported by Teuteberg and Del-
gado (P = 0.53, P = 0.34, respectively) [66,67], and it was
not analyzed by Crespo Leiro [68]. Episodes of rejection at
12 and 24 months were reported to be similar in both the
groups [60,65,66], lower in the SFM group (P < 0.0001)
[63], or not analyzed [67–69], as well as the incidence of
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Summarizing the authors’ conclusions, the use of CSs for
more than 1 year after transplantation seems unlikely to
provide clinical benefit [61]; moreover, in SFM group,
good long-term outcomes and no worsening of allograft
function were observed [65], with a trend toward reduction
in rejection incidence, number of infection episodes [60],
and hypertension rate [68].
Pediatric experiences
There are four studies on pediatric experiences, one pro-
spective [70] and three retrospectives [26,71,72] (Table 4).
Three studies were classified as high quality [70–72], and
only one was of medium quality [26]. Two retrospective
publications on steroid-free protocols come to similar con-
clusions [26,72]. Livi et al. [26] reported their experience
on 30 pediatric HTx patients receiving CsA/AZA alone,
observing 1-, 5-, and 10-year overall patient survival at
80%, 76%, and 76%, respectively, a rejection rate of 1.2 epi-
sodes per patient, and an infection frequency of 0.2 epi-
sodes per patient. Singh et al. [72] reported the outcome of
55 HTx pediatric recipients with a post-transplant survival
of 91% at 6 months and 88% at 12 and 24 months,
whereas freedom from first rejection was still over 80% at
2 years.
Two publications reported early and late steroid with-
drawal. Canter et al. [70] prospectively evaluated the feasi-
bility of steroids withdrawing at 6 to 12 months after HTx
in 21 pediatric patients. Four of 21 patients (24%) had
rejection after steroid withdrawal, and survival rate was
88% at 6 months. Similar results were obtained in a retro-
spective study by Leonard et al. [71] who reported in 77
HTx pediatric patients a survival of 88, 85, and 70% at 1, 5,
and 10years, respectively, with an overall rejection rate of
0.03 episodes/patient/year. The author concluded that this
regimen presented a very good rejection-free survival.
In conclusion, experience in pediatric HTx has been
shown in many centers to have excellent outcomes by com-
plete steroid avoidance. Thus today, the “one size fits all”
approach to immunosuppressive therapy in pediatric patients
is an obsolete concept, and the ultimate target should be to
tailor immunosuppression for any single case [73].
Limitations
Despite the application of the Cochrane and GRACE crite-
ria, the real quality of studies was sometimes difficult to
evaluate. Most studies were retrospectives, and their design
or analysis seems to be not always appropriate to evaluate
outcomes, and moreover, those have been conducted “as
treated” demonstrating only the feasibility and the efficacy
of the new therapy. This means that in most cases, where
































































































































































































































































































































































































































































































































































































































































































































526 © 2014 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT 27 (2014) 515–529
Steroid-free and steroid withdrawal protocols in heart transplantation Baraldo et al.
defined as group of patients in whom steroid avoidance or
withdrawal was finally achieved. Also, multivariable model-
ing was applied only in few studies and so probably a
immunologically privileged group in which steroids could
be effectively withdrawn was compared to the rest of the
study group.
Conclusions
Many of the cited studies showing good results of steroid
weaning were those where steroid withdrawal was
attempted in all patients, and then, 30–50% of weaned
patients were compared with the patient cohort in which
weaning was not successful. The conclusion coming from
different studies that steroid weaning could be advanta-
geous is a leap of faith as usually two different patient pop-
ulations were compared. For example, the Yamani study
[56] included only patients that were thought to be immu-
nologically at low risk (PRA < 10%, virtual and actual
cross-match negative).
In addition to all the studies reported in this review,
other trials, not focusing specifically on steroids, provide
important information about efficacy of steroid with-
drawal. For instance, in the TICTAC study where steroids
were discontinued after 8 weeks in all patients (150
patients), the long-term outcome was excellent [74].
In recent guidelines reported by the International Society
of Heart and Lung Transplantation (ISHLT) [75], CS
avoidance, early CS weaning, or very low-dose maintenance
CS therapy are all acceptable therapeutic approaches with
level of evidence B. In the present review, the studies ana-
lyzed came overall to similar conclusions in terms of bene-
fits and adverse consequences of both CS-free and CS-
withdrawal protocols after HTx: 1) good mid- and long-
term graft/patient survival; 2) higher incidence of acute
rejection in CS-free approach; 3) a variable incidence of
infection episodes; 4) lower serum cholesterol levels; 5)
possibly lower hypertension rate; 6) amelioration of weight
control; and 7) slightly lower risk of diabetes and bone loss.
Accordingly, CS-free therapy should be advisable and
sometimes mandatory in pediatric age, in cases of active
infection, IDDM, familial metabolic disorders/obesity,
severe osteoporosis, and in elderly patients. In all HTx
patients, CS withdrawal seems to be feasible (any age, sex,
and race; at present, a success rate of 50–80%) and safe
(does not increase rejection-related mortality and has no
adverse impact on survival) and maybe more practicable
when combined with the new drugs. Defining what is bet-
ter, whether early or late withdrawal, does not seem cur-
rently possible because the number of published trials is
still limited. Anyhow, early steroid withdrawal should be
used in recipients with a lower propensity to rejection, also
in the long term.
The very critical aspect is that many of the cited
studies were reporting a successful attempt of steroid
withdrawal in more than 50% of patients treated and
those compared with patients in which steroids weaning
was not successfully achieved. This incorrect methodol-
ogy can favor erroneous interpretation of the results, as
the feasibility and efficacy of steroids avoidance or
withdrawal reflect probably an immune-privileged subset
of patients.
In conclusion, a prospective randomized trial should be
carried out to verify whether CS withdrawal or CS-free
maintenance improve long-term outcome following HTx
and impact significantly on quality of life by reducing com-
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